Search

Your search keyword '"Whorwell, Peter"' showing total 14 results
Start Over Author "Whorwell, Peter" Journal gut
14 results on '"Whorwell, Peter"'

4. Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome

Author

Wouters, Mira M, Lambrechts, Diether, Knapp, Michael, Cleynen, Isabelle, Whorwell, Peter, Agréus, Lars, Dlugosz, Aldona, Schmidt, Peter Thelin, Halfvarson, Jonas, Simrén, Magnus, Ohlsson, Bodil, Karling, Pontus, Van Wanrooy, Sander, Mondelaers, Stéphanie, Vermeire, Severine, Lindberg, Greger, Spiller, Robin, Dukes, George, DʼAmato, Mauro, and Boeckxstaens, Guy

Published
2014
Full Text
View/download PDF

8. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)

Author

Lam, Ching, primary, Tan, Wei, additional, Leighton, Matthew, additional, Hastings, Margaret, additional, Lingaya, Melanie, additional, Falcone, Yirga, additional, Zhou, Xiaoying, additional, Xu, Luting, additional, Whorwell, Peter, additional, Walls, Andrew F, additional, Zaitoun, Abed, additional, Montgomery, Alan, additional, and Spiller, Robin, additional

Published
2015
Full Text
View/download PDF

10. Genetic variants inCDC42andNXPH1as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome

Author

Wouters, Mira M, primary, Lambrechts, Diether, additional, Knapp, Michael, additional, Cleynen, Isabelle, additional, Whorwell, Peter, additional, Agréus, Lars, additional, Dlugosz, Aldona, additional, Schmidt, Peter Thelin, additional, Halfvarson, Jonas, additional, Simrén, Magnus, additional, Ohlsson, Bodil, additional, Karling, Pontus, additional, Van Wanrooy, Sander, additional, Mondelaers, Stéphanie, additional, Vermeire, Severine, additional, Lindberg, Greger, additional, Spiller, Robin, additional, Dukes, George, additional, D'Amato, Mauro, additional, and Boeckxstaens, Guy, additional

Published
2013
Full Text
View/download PDF

11. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit

Author

Tooth, David, primary, Garsed, Klara, additional, Singh, Gulzar, additional, Marciani, Luca, additional, Lam, Ching, additional, Fordham, Imogen, additional, Fields, Annie, additional, Banwait, Rawinder, additional, Lingaya, Melanie, additional, Layfield, Robert, additional, Hastings, Maggie, additional, Whorwell, Peter, additional, and Spiller, Robin, additional

Published
2013
Full Text
View/download PDF

12. A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

Author

Ching Lam, Wei Tan, Leighton, Matthew, Hastings, Margaret, Lingaya, Melanie, Falcone, Yirga, Xiaoying Zhou, Luting Xu, Whorwell, Peter, Walls, Andrew F., Zaitoun, Abed, Montgomery, Alan, and Spiller, Robin

Subjects
IRRITABLE colon treatment, MESALAMINE, DIARRHEA, PLACEBOS, RANDOMIZED controlled trials, ABDOMINAL pain, THERAPEUTICS
Abstract

Introduction: Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms. We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily versus placebo for 3 months in patients with Rome III criteria IBS-D. Primary outcome was daily average stool frequency during weeks 11-12; secondary outcomes were abdominal pain, stool consistency, urgency and satisfactory relief of IBS symptoms. Methods: Participants were randomised after a 2-week baseline stool diary. All participants completed a 12-week stool diary and at the end of each week recorded the presence of 'satisfactory relief of IBS symptoms'. Results: 136 patients with IBS-D (82 women, 54 men) were randomised, 10 patients withdrew from each group. Analysis by intention to treat showed the daily average stool frequency during weeks 11 and 12 were mean (SD), 2.8 (1.2) in mesalazine and 2.7 (1.9) in the placebo group with no significant group difference, (95% CI) 0.1 (-0.33 to 0.53), p=0.66. Mesalazine did not improve abdominal pain, stool consistency nor percentage with satisfactory relief compared with placebo during the last two-weeks follow-up. Conclusions: This study does not support any clinically meaningful benefit or harm of mesalazine compared with placebo in unselected patients with IBS-D. More precise subtyping based on underlying disease mechanisms is needed to allow more effective targeting of treatment in IBS. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

14. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα

Author

Swan, Caroline, primary, Duroudier, Nathalie P, additional, Campbell, Eugene, additional, Zaitoun, Abed, additional, Hastings, Margaret, additional, Dukes, George E, additional, Cox, Joanne, additional, Kelly, Fiona M, additional, Wilde, Jonathan, additional, Lennon, Mark G, additional, Neal, Keith R, additional, Whorwell, Peter J, additional, Hall, Ian P, additional, and Spiller, Robin C, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results